Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 Dividend Yield % is 0.60% as of Jul. 28, 2026, which is 5% above its 10-year median of 0.57. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 150 Biotechnology companies, Concord Biotech ranks worse than 76% on this metric.
As of today (2026-07-28), the Trailing Annual Dividend Yield of Concord Biotech is 0.60%.
Warning Sign:
Concord Biotech Ltd stock Dividend Yield % is close to 1-year low.
The historical rank and industry rank for Concord Biotech's Dividend Yield % or its related term are showing as below:
BOM:543960'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.34 Med: 0.57 Max: 1.06
Current: 0.6
During the past 7 years, the highest Dividend Yield of Concord Biotech was 1.06%. The lowest was 0.34%. And the median was 0.57%.
BOM:543960's Dividend Yield % is ranked worse than 76% of 150
companies
in the Biotechnology industry
Industry Median: 1.325
vs BOM:543960: 0.60
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Concord Biotech's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Dividend Yield % Comparison
For the Biotechnology subindustry, Concord Biotech's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Concord Biotech Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 7.550000
2026-07-24
2026-07-24
2026-08-30
Cash Dividend
annually
INR:INR 1.000000
INR 10.700000
2025-09-03
2025-09-03
2025-09-22
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Concord Biotech's Trailing Annual Dividend Yield (%) for Today is calculated as
Concord Biotech's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
7.55
/
1257.00
=
0.60 %
Current Share Price is ₹1257.00. Concord Biotech's Dividends per Share for the forward twelve months is calculated as ₹7.55 * 1 = ₹7.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a Dividend Yield % of 0.60% as of Jul. 28, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Concord Biotech and its competitors. This is near median its historical median of 0.57. Over the past decade, Concord Biotech's Dividend Yield % has ranged from 0.34 to 1.06. According to the industry distribution chart, Concord Biotech ranks #114 out of 150 companies in the Biotechnology industry, placing it in the top 76%.
Is Concord Biotech's Dividend Yield % too high?
Concord Biotech's current Dividend Yield % of 0.60% is near median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 1.06. The Biotechnology industry median Dividend Yield % is 1.33. Concord Biotech's value of 0.60% is 54.7% below this industry median. Based on the distribution chart, Concord Biotech ranks #114 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #114 out of 150 companies for Dividend Yield %. This places Concord Biotech in the lower half of its industry. The industry median Dividend Yield % is 1.33. Concord Biotech's value of 0.60% is 54.7% below this benchmark. Historically, Concord Biotech's own Dividend Yield % has ranged from 0.34 to 1.06 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 1.33, Concord Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.33, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Dividend Yield % of 0.60% is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Dividend Yield % is 0.60%, which is near median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current Dividend Yield % is 0.60%, which is near median its 10-year median of 0.57 and 54.7% below the Biotechnology industry median of 1.33. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Dividend Yield % is 0.60% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Dividend Yield %: 0.60% (near median its 10-year median of 0.57)
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
Industry Position: 54.7% below the Biotechnology median (#114 of 150)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
